Elevated Urinary Albumin Predicts Increased Time in Range After Initiation of SGLT2 Inhibitors in Individuals with Type 1 Diabetes on Sensor-augmented Pump Therapy

Overview

Journal Diabetol Int

Specialty Endocrinology

Date 2024 Oct 29

PMID 39469555

Authors

Yuka Suganuma

Mizuki Ishiguro

Takayuki Ohno

Rimei Nishimura

Affiliations

Soon will be listed here.

Abstract

Aims: We aimed to investigate potential predictors of effectiveness of SGLT2 inhibitors (SGLT2i) in individuals with type 1 diabetes (T1D) on sensor-augmented pump (SAP) therapy.

Methods: We included individuals with T1D receiving SAP therapy at our hospital who were newly initiated on SGLT2i between 2019 and 2020 and were followed for at least 1 year. Data on BMI, blood tests, and continuous glucose monitoring (CGM) were compared before and 12 months after initiation of SGLT2i. Predictors of incremental increases in time in range (ΔTIR) were explored using a multiple regression analysis. Cutoff values for the predictors were determined using an ROC curve analysis.

Results: A total of 17 individuals (females, 70.6%; median age, 44.0 years) were included, excluding three individuals who discontinued SGLT2i due to side effects. During follow-up, their median BMI decreased significantly ( = 0.013), while no significant change was seen in their total daily dose of insulin, basal-to-total insulin ratio. Again, their HbA1c, TIR, and time above range (TAR) improved significantly ( = 0.004, = 0.003, and = 0.003, respectively), while their time below range (TBR) showed no significant change. The predictor of increased ΔTIR was high urinary albumin-to-creatinine ratio (UACR) at baseline ( = 0.026) only, with the cutoff value determined to be 28.0 mg/g Cr or higher (AUC = 0.82, = 0.003).

Conclusions: It may be suggested that individuals with T1D on SAP therapy and having near-microalbuminuria or higher could be expected to show significant improvement in TIR.

Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-024-00743-4.

References

Kariyawasam D, Morin C, Casteels K, Le Tallec C, Sfez A, Godot C . Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial. Lancet Digit Health. 2022; 4(3):e158-e168. DOI: 10.1016/S2589-7500(21)00271-5. View

Osorio H, Coronel I, Arellano A, Franco M, Escalante B, Bautista R . Ursodeoxycholic acid decreases sodium-glucose cotransporter (SGLT2) expression and oxidative stress in the kidney of diabetic rats. Diabetes Res Clin Pract. 2012; 97(2):276-82. DOI: 10.1016/j.diabres.2012.02.022. View

Cherney D, Zinman B, Inzucchi S, Koitka-Weber A, Mattheus M, von Eynatten M . Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017; 5(8):610-621. DOI: 10.1016/S2213-8587(17)30182-1. View

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

Dandona P, Mathieu C, Phillip M, Hansen L, Griffen S, Tschope D . Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5(11):864-876. DOI: 10.1016/S2213-8587(17)30308-X. View

Rosenstock J, Marquard J, Laffel L, Neubacher D, Kaspers S, Cherney D . Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care. 2018; 41(12):2560-2569. DOI: 10.2337/dc18-1749. View

Haidar A, Lovblom L, Cardinez N, Gouchie-Provencher N, Orszag A, Tsoukas M . Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial. Nat Med. 2022; 28(6):1269-1276. DOI: 10.1038/s41591-022-01805-3. View

Bergenstal R, Tamborlane W, Ahmann A, Buse J, Dailey G, Davis S . Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010; 363(4):311-20. DOI: 10.1056/NEJMoa1002853. View

Vallon V, Rose M, Gerasimova M, Satriano J, Platt K, Koepsell H . Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2012; 304(2):F156-67. PMC: 3543626. DOI: 10.1152/ajprenal.00409.2012. View

10.

Avgerinos I, Manolopoulos A, Michailidis T, Kitsios K, Liakos A, Karagiannis T . Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab. 2020; 23(3):822-831. DOI: 10.1111/dom.14291. View

11.

Rodbard D . Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes. Diabetes Technol Ther. 2017; 19(S3):S25-S37. PMC: 5467105. DOI: 10.1089/dia.2017.0035. View

12.

Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E . Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018; 41(9):1938-1946. DOI: 10.2337/dc18-0623. View

13.

Taylor S, Blau J, Rother K, Beitelshees A . SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes Endocrinol. 2019; 7(12):949-958. PMC: 6872914. DOI: 10.1016/S2213-8587(19)30154-8. View

14.

Matsuoka A, Hirota Y, Urai S, Hamaguchi T, Takeuchi T, Miura H . Effect of switching from conventional continuous subcutaneous insulin infusion to sensor augmented pump therapy on glycemic profile in Japanese patients with type 1 diabetes. Diabetol Int. 2019; 9(3):201-207. PMC: 6224909. DOI: 10.1007/s13340-018-0344-4. View

15.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

16.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

17.

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

18.

Collyns O, Meier R, Betts Z, Chan D, Frampton C, Frewen C . Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes. Diabetes Care. 2021; 44(4):969-975. DOI: 10.2337/dc20-2250. View

19.

Coronel-Restrepo N, Blanco V, Palacio A, Ramirez-Rincon A, Arbelaez S, Duque V . Real-world effectiveness and safety of sensor-augmented insulin pump therapy in adults with type 1 diabetes: Long-term follow-up. Endocrinol Diabetes Nutr (Engl Ed). 2021; 68(8):567-572. DOI: 10.1016/j.endien.2021.11.009. View

20.

Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S . Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis. Horm Metab Res. 2015; 47(9):686-92. DOI: 10.1055/s-0034-1395609. View